Company profile

Sumitomo Pharma

4506 · TSE

Public Market Listing

4506TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Sumitomo Pharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
3Approved
1Phase 3 / Filed
3Phase 1–2 / Early
5Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Apomorphine sublingual film (Kynmobi)(Kynmobi)
Approved
dopamineSmall molecule
Parkinson's Disease
Eslicarbazepine acetate(Aptiom)
Approved
Voltage-gated sodium channelSmall molecule
Epilepsy
Lurasidone
Approved
Dopamine D2/D3 receptor + 5-HT7 receptor · Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia
Ulotaront
Phase 3
TAAR1 (trace amine-associated receptor 1)Small molecule
Schizophrenia
DSP-1083
Phase 2
Allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergicCell therapy
Parkinson's Disease
Enzomenib
Phase 2
Menin-KMT2A protein-protein interactionSmall molecule
Acute Myeloid Leukemia
SEP-380135
Phase 1
Undisclosed / early pipelineSmall molecule
Major Depressive DisorderSchizophrenia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.